Gain-of-function mutations of KIT are detectable in many cancers, including gastrointestinal stromal tumor (GIST) [36,37], melanoma [38], seminoma [39], mastocytosis [40], and acute myeloid leukemia (AML) [41]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.